Back

Safety and efficacy of DAPAGLIFLOZIN in patients with systemic right ventricular dysfunction: Preliminary results

15 April 2024 (16:42 - 16:48)
Organised by: Logo
Seminar Presentation Part of: Session 4: Top 5 Abstract Oral Presentations Adult Congenital Heart Disease (ACHD) Open Access EuroACHD 2024 WG on Adult Congenital Heart Disease

About the speaker

Photo
Doctor Mathieu Albertini

Paris (France)

4 More presentations in this session

Presentation thumbnail
A validated mortality score for adults with a Fontan circulation: Fontan Adult Brompton (FAB) score
Doctor A. Arvanitaki (Thessaloniki, GR)
Slides
Presentation thumbnail
Single center experience in treatment of adults with Fontan circulation using Sodium Glucose Cotransporter-2 inhibitors
Doctor P. Skorek (Krakow, PL)
Slides
Presentation thumbnail
A review of more than 2 decades of Heart Lung Transplants at The Freeman Hospital
Doctor A. Henry (Johor Bahru, MY)
Slides
Presentation thumbnail
Risk of heart failure after cancer diagnosis in CHD - patients
Doctor C. Karazisi (Gothenburg, SE)
Slides

Access the full session

Session thumbnail
Session 4: Top 5 Abstract Oral Presentations

The Event

Event poster

EuroACHD 2024

15 April 2024 16:42 CET
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function in HFrEF patients
26 April 2024
thumbnail
Congress Session
Imaging the stressed right ventricle
11 May 2023
thumbnail
Congress Session
Advances in medical therapy in heart failure
20 May 2025
thumbnail
Congress Presentation
Right ventricle function improvement with sacubitril/valsartan therapy
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources